BackgroundAutism spectrum disorder (ASD) has a strong genetic etiology. Germline mutation in the tumor suppressor gene PTEN is one of the best described monogenic risk cases for ASD. Animal modeling of cell-specific Pten loss or mutation has provided insight into how disruptions to the function of PTEN affect neurodevelopment, neurobiology, and social behavior. As such, there is a growing need to understand more about how various aspects of PTEN activity, cell-compartment-specific functions, contribute to certain neurological or behavior phenotypes.MethodsTo understand more about the relationship between Pten localization and downstream effects on neurophenotypes, we generated the nuclear-predominant PtenY68H/+ mouse. We subjected the PtenY68H/+ mouse to morphological and behavioral phenotyping, including the three-chamber sociability and marble burying tests. We subsequently performed in vivo and in vitro cellular phenotyping and concluded the work with a transcriptomic survey of the PtenY68H/+ cortex, which profiled gene expression.ResultsDespite no significant changes in downstream canonical Pten signaling, we found that the PtenY68H/+ mouse presents with macrocephaly, social impairment (i.e., decreased sociability, decreased preference for novel social stimuli, and increased perseverative activity), with significant microglial activation accompanied by enhanced phagocytosis. Because of lack of canonical signaling alterations, we turned to analyzing the neural transcriptomes, which revealed overexpression of many genes involved in neuroinflammation and neuronal function, including oxytocin. Oxytocin transcript was 5-fold overexpressed (P = 0.0018) and oxytocin protein was strongly overexpressed in the PtenY68H/+ hypothalamus. ConclusionsThe nuclear-predominant PtenY68H/+ model has clarified that Pten dysfunction links to microglial pathology and that timed decreased in Pten levels is the provoking insult. Notably, we demonstrate that Pten dysfunction associates with changes in the oxytocin system, an important connection between a prominent ASD risk gene and a potent neuroendocrine regulator of social behavior. Ultimately, the findings from this work may reveal important biomarkers and/or novel therapeutic modalities that could be explored in individuals with germline mutations in PTEN with ASD.